Scholay

学术搜索 · AI 审稿 · LaTeX 协作

Prevalence of comorbidities and their impact on prognosis among patients with rifampicin-resistant tuberculosis: a multicenter retrospective cohort study in China

作者:Li‐Ping Zou, Zhili Li, Qing Pan, Jiaojie Ma, Peijun Tang, Wanli Kang, Qing Chen, Zhengyu Shi, Xianzhen Tang, Chunhui Guo, Juan Du, Qingdong Zhu, Song Yang, Zhanlin Chang, Zhouli Guo, Shenjie Tang, Guihui Wu · 发表于:Scientific Reports · 年份:2025 · DOI:10.1038/s41598-025-22780-y · 被引用次数:2 · 研究领域:Tuberculosis Research and Epidemiology、Diagnosis and treatment of tuberculosis、Pneumocystis jirovecii pneumonia detection and treatment

Comorbidities are a significant factor affecting the prognosis of patients with rifampicin-resistant tuberculosis (RR-TB). We evaluated the prevalence of comorbidities and their prognostic effects in a Chinese RR-TB cohort. In this study, we reviewed the clinical data of RR-TB patients who started anti-tuberculosis treatment in China between May 2018 and April 2020 by conducting a multicenter cohort study. A log-binomial regression model was used to analyze the relationship between comorbidities and the treatment outcomes of RR-TB. The burden of comorbidities among RR-TB patients in China was heavy, with 49.45% (670/1355) experiencing at least one comorbidity. The most common comorbidities were diabetes (17.79%), followed by other respiratory diseases (11.14%), other liver and kidney diseases (5.31%), hypertension (5.24%), immunodeficiency (4.94%), viral hepatitis or carriers (3.91%), severe heart disease (2.58%), tumours (1.11%), and chronic kidney disease or renal insufficiency (0.74%). Diabetes (RR = 1.31), severe heart disease (RR = 1.70), tumours (RR = 1.89), hypertension (RR = 1.28), aged ≥ 60 years (RR = 1.64) and 45-59 years (RR = 1.38), ethnic minorities (RR = 1.58), retreatment cases (RR = 1.34), and those not using the bedaquiline regimen (RR = 1.92) significantly increased the risk of unfavorable treatment outcomes. While higher education or above (RR = 0.49), employment (RR = 0.51), and having a normal (R = 0.53) or overweight (R = 0.56) BMI could reduce the risk...